Effect and safety of NN9535 in weight management (NN9536-4382)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224531

Enrollment

360

Registered

2019-01-29

Start date

2019-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight or obesity

Interventions

investigational material(s) Generic name etc : NN9535 INN of investigational material : - Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) Dosage and Adm

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI >= 27.0 kg/m2 with >= 2 weight related comorbidities or BMI >= 35.0 kg/m2 with >= 1 weight related comorbidity

Exclusion criteria

Exclusion criteria: Severe heart failure, History of pancreatitis, Severe psychological disorder, other

Design outcomes

Primary

Measure	Time frame
efficacy Change from baseline in body weight (%)	—

Secondary

Measure	Time frame
safety Number of treatment emergent adverse events (TEAEs) from baseline	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026